Company

Trefoil Therapeutics, Inc.

San Diego biotech founded in 2014 developing therapies to restore vision in patients with corneal diseases.

About

Founded in 2014 in San Diego, US, Trefoil Therapeutics, Inc. develops treatments to restore vision for patients with corneal diseases. Its focus is TTHX1114, an engineered FGF1, developed as an intracameral injection for corneal endothelial decompensation and a topical formulation for ocular surface damage. CEO David Eveleth leads the company. In December 2021 it raised USD 28 mn in Series A funding from investors including AJU IB Investment and Access Industries.

4Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in